Hospira, Delcath Systems, Valeant Pharma, and Alkermes Under StockCall's Microscope

Hospira, Delcath Systems, Valeant Pharma, and Alkermes Under StockCall's Microscope
By StockCall.com
Published: Tuesday, Apr. 9, 2013 - 5:08 am
LONDON, April 9, 2013

Drug delivery companies such as Hospira Inc. (NYSE: HSP), Delcath Systems Inc. (NASDAQ: DCTH), Valeant Pharmaceuticals International Inc. (NYSE: VRX) and Alkermes Plc (NASDAQ: ALKS) are evaluating the impact of President Obama's Affordable Care Act (ACA). The ACA was upheld by the Supreme Court last year, and is the biggest overhaul of the healthcare industry in decades. While the healthcare industry is expected to benefit from the ACA in the long-term as the reform will lead to increase in the number of insured individuals, critics of ACA say that the reform will lead to higher costs for the industry. On Monday, drug delivery stocks ended on a mixed note even as the broad market edged higher. StockCall has released full comprehensive research on HSP, DCTH, VRX, and ALKS and these free technical analyses can be downloaded by signing up at

http://www.stockcall.com/technicalanalysis

Shares of Hospira Inc. edged lower on Monday; however, the gains were limited. The stock closed 0.26% lower at $30.57 on volume of 1.08 million. Hospira's shares touched an intra-day low of $30.43. The company's shares have seen a series of lows over the last few trading sessions, which is a bearish signal. The negative trend is further confirmed the stock's MACD chart. The MACD has slipped below the signal line and the zero-line. Year-to-date, the stock has fallen more than 2%, even as the broad market has gained nearly 9.60%. Free technical analysis on HSP available by signing up at

http://www.StockCall.com/HSP040913.pdf

Shares of Delcath Systems Inc. tumbled in trading on Monday. The stock closed 6.78% lower at $1.65 on above average volume of 4.72 million. The stock has fallen more than 7.80% in the last three sessions, which is a bearish signal. Despite the recent losses, shares of DCTH have gained more than 34% in the last three sessions. The stock is currently trading more than 48% below its 52-week high. The company's 50-day moving average has recently moved above the 200-day moving average, forming a "golden cross". However, the stock's MACD has slipped below the signal line, which is a bearish signal. Register today and access the free research on DCTH at

http://www.StockCall.com/DCTH040913.pdf

Valeant Pharmaceuticals International Inc.'s shares edged higher on Monday; however, the gains were limited. The stock closed 0.46% higher at $72.12 on volume of 934,206. The stock touched an intra-day high of $71.28 yesterday. Valeant Pharma's shares are currently trading close to their 52-week high of $76.56. The stock has gained more than 20% so far this year, compared to a gain of nearly 9.60% for the S&P 500. However, its technical indicators suggest that market sentiment has turned bearish on the stock. The free report on VRX can be downloaded by signing up now at

http://www.StockCall.com/VRX040913.pdf

Shares of Alkermes Plc rose sharply on Monday, tracking gains in the broad market. The stock closed 1.43% higher at $22.67 on volume of 636,367. The stock touched an intra-day high of $22.70. Despite Monday's gains, Alkermes' shares have fallen more than 2.20% in the last three sessions. Year-to-date, however, the stock has gained more than 22%, outperforming the S&P 500. The company's shares are trading above their 50-day and 200-day moving averages. Free report on ALKS can be accessed by registering at

http://www.StockCall.com/ALKS040913.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

http://www.stockcall.com

SOURCE StockCall.com

Read more here: http://www.sacbee.com/2013/04/09/5327225/hospira-delcath-systems-valeant.html#storylink=cpy

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.